

APPLICANT(S): GEWIRTZ, Alan M.

SERIAL NO.: 10/593,578

FILED: June 4, 2007

Page 2

AMENDMENTS TO THE CLAIMS

Please amend the claims to read as follows:

1. (Currently amended) A method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting said bcl-6-expressing cell with a composition that reduces an amount of said bcl-6 protein or of a ribonucleic acid molecule encoding said bcl-6 protein, thereby inducing apoptosis in a bcl-6-expressing cell, wherein said composition comprises a nucleic acid molecule complementary to ~~all or portion of~~ the sequence set forth in SEQ ID NO: 6.
2. (Original) The method of claim 1, wherein said cell is a lymphoma cell.
3. (Original) The method of claim 2, wherein said lymphoma cell is a non-Hodgkin's lymphoma cell.
4. (Currently amended) A method of treating a subject with a lymphoma comprising a bcl-6-expressing lymphoma cell, comprising contacting said subject with a composition that reduces an amount of said bcl-6 protein or of a ribonucleic acid molecule encoding said bcl-6 protein, thereby treating a said subject with said lymphoma ~~cancer comprising a bcl-6 expressing cell~~, wherein said composition comprises a nucleic acid molecule complementary to ~~all or portion of~~ the sequence set forth in SEQ ID NO: 6.
5. (Original) The method of claim 4, wherein said lymphoma is a non-Hodgkin's lymphoma.
6. (Currently amended) A method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting said bcl-6-expressing cell with a composition comprising a nucleic acid molecule complementary to ~~all or portion of~~ the sequence set forth in SEQ ID NO: 6, thereby inducing apoptosis in a bcl-6-expressing cell.
7. (Original) The method of claim 6, wherein said cell is a lymphoma cell.
8. (Original) The method of claim 7, wherein said lymphoma cell is a non-Hodgkin's

APPLICANT(S): GEWIRTZ, Alan M.

SERIAL NO.: 10/593,578

FILED: June 4, 2007

Page 3

lymphoma cell.

9. (Original) The method of claim 6, wherein said nucleic acid molecule is an oligo-deoxyribonucleic acid (ODN) molecule.
10. (Cancelled).
11. (Currently amended) A method of treating a subject with a lymphoma comprising a bcl-6-expressing lymphoma cell, comprising contacting said subject with a composition comprising a nucleic acid molecule complementary to ~~all or portion of~~ the sequence set forth in SEQ ID NO: 6, thereby treating ~~a~~ said subject with said lymphoma ~~aneer~~ comprising a bcl-6-expressing cell.
12. (Original) The method of claim 11, wherein said lymphoma is a non-Hodgkin's lymphoma.
13. (Original) The method of claim 11, wherein said nucleic acid molecule is an oligo-deoxyribonucleic acid (ODN) molecule.
14. (Cancelled).
15. (Currently amended) A method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting said bcl-6-expressing cell with a composition comprising a nucleic acid molecule corresponding to ~~all or portion of~~ the sequence set forth in SEQ ID NO: 6, thereby inducing apoptosis in a bcl-6-expressing cell.
16. (Original) The method of claim 15, wherein said cell is a lymphoma cell.
17. (Original) The method of claim 16, wherein said lymphoma cell is a non-Hodgkin's lymphoma cell.
18. (Original) The method of claim 15, wherein said nucleic acid molecule is a short interfering ribonucleic acid (siRNA) molecule.
19. (Original) The method of claim 15, wherein said nucleic acid molecule is a short hairpin RNA (shRNA) molecule.

APPLICANT(S): GEWIRTZ, Alan M.

SERIAL NO.: 10/593,578

FILED: June 4, 2007

Page 4

20. (Cancelled).
21. (Currently amended) A method of treating a subject with a lymphoma comprising a bcl-6-expressing lymphoma cell, said method comprising contacting said subject with a composition comprising a nucleic acid molecule corresponding to ~~all or portion of~~ the sequence set forth in SEQ ID NO: 6, thereby treating a said subject with said lymphoma ~~cancer comprising a bcl-6-expressing cell~~.
22. (Original) The method of claim 21, wherein said lymphoma is a non-Hodgkin's lymphoma.
23. (Original) The method of claim 21, wherein said nucleic acid molecule is a short interfering ribonucleic acid (siRNA) molecule.
24. (Original) The method of claim 21, wherein said nucleic acid molecule is a short hairpin RNA (shRNA) molecule.
25. (Cancelled).
26. (Currently amended) A method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting said bcl-6-expressing cell with a vector expressing a nucleic acid molecule complementary to ~~all or portion of~~ the sequence set forth in SEQ ID NO: 6, thereby inducing apoptosis in a said bcl-6-expressing cell.
27. (Original) The method of claim 26, wherein said cell is a lymphoma cell.
28. (Original) The method of claim 27, wherein said lymphoma cell is a non-Hodgkin's lymphoma cell.
29. (Original) The method of claim 26, wherein said vector is a lentiviral vector.
30. (Original) The method of claim 26, wherein said nucleic acid molecule is an oligo-deoxyribonucleic acid (ODN) molecule.
31. (Cancelled).

APPLICANT(S): GEWIRTZ, Alan M.

SERIAL NO.: 10/593,578

FILED: June 4, 2007

Page 5

32. (Currently amended) A method of treating a subject with a lymphoma comprising a bcl-6-expressing lymphoma cell, comprising contacting said subject with a vector expressing a nucleic acid molecule complementary to ~~all or portion of~~ the sequence set forth in SEQ ID NO: 6, thereby treating ~~a~~ said subject with said lymphoma ~~cancer~~ ~~comprising a bcl-6-expressing cell~~.
33. (Original) The method of claim 32, wherein said lymphoma is a non-Hodgkin's lymphoma.
34. (Original) The method of claim 32, wherein said vector is a lentiviral vector.
35. (Original) The method of claim 32, wherein said nucleic acid molecule is an oligo-deoxyribonucleic acid (ODN) molecule.
36. (Cancelled).
37. (Currently amended) A method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting said bcl-6-expressing cell with a vector expressing a nucleic acid molecule corresponding to ~~all or portion of~~ the sequence set forth in SEQ ID NO: 6, thereby inducing apoptosis in ~~a~~ said bcl-6-expressing cell.
38. (Original) The method of claim 37, wherein said cell is a lymphoma cell.
39. (Original) The method of claim 38, wherein said lymphoma cell is a non-Hodgkin's lymphoma cell.
40. (Original) The method of claim 37, wherein said vector is a lentiviral vector.
41. (Original) The method of claim 37, wherein said nucleic acid molecule is a short interfering ribonucleic acid (siRNA) molecule.
42. (Original) The method of claim 37, wherein said nucleic acid molecule is a short hairpin RNA (shRNA) molecule.
43. (Cancelled).

APPLICANT(S): GEWIRTZ, Alan M.

SERIAL NO.: 10/593,578

FILED: June 4, 2007

Page 6

44. (Currently amended) A method of treating a subject with a lymphoma comprising a bcl-6-expressing lymphoma cell, comprising contacting said subject with a vector expressing a nucleic acid molecule corresponding to ~~all or portion~~ of the sequence set forth in SEQ ID NO: 6, thereby treating a said subject with said lymphoma ~~caner~~ comprising a ~~bcl-6-expressing~~ cell.
45. (Original) The method of claim 44, wherein said lymphoma is a non-Hodgkin's lymphoma.
46. (Original) The method of claim 44, wherein said vector is a lentiviral vector.
47. (Original) The method of claim 44, wherein said nucleic acid molecule is a short interfering ribonucleic acid (siRNA) molecule.
48. (Original) The method of claim 44, wherein said nucleic acid molecule is a short hairpin RNA (shRNA) molecule.
49. (Cancelled).
50. (Withdrawn) An isolated nucleic acid molecule having a sequence selected from the sequences set forth in SEQ ID No: 1-10.
51. (Withdrawn) An oligo-deoxyribonucleic acid (ODN) molecule having a sequence corresponding to the isolated nucleic acid molecule of claim 50 or a fragment thereof, wherein said fragment is about 21-23 nucleotide in length.
52. (Withdrawn) A composition comprising the isolated nucleic acid molecule of claim 50.
53. (Withdrawn) A vector comprising the isolated nucleic acid molecule of claim 50.
54. (Withdrawn) A cell comprising the isolated nucleic acid molecule of claim 50.
55. (Withdrawn) An isolated nucleic acid molecule having a sequence complementary to a sequence selected from the sequences set forth in SEQ ID No: 1-10.

APPLICANT(S): GEWIRTZ, Alan M.

SERIAL NO.: 10/593,578

FILED: June 4, 2007

Page 7

56. (Withdrawn) A short interfering ribonucleic acid (siRNA) molecule having a sequence corresponding to a fragment of the isolated nucleic acid molecule of claim 55, wherein said fragment is about 21-23 nucleotide in length.
57. (Withdrawn) A short hairpin RNA (shRNA) molecule comprising a sequence corresponding to a fragment of the isolated nucleic acid molecule of claim 55, wherein said fragment is about 19-23 nucleotide in length.
58. (Withdrawn) A composition comprising the isolated nucleic acid molecule of claim 55.
59. (Withdrawn) A vector comprising the isolated nucleic acid molecule of claim 55.
60. (Withdrawn) A cell comprising the isolated nucleic acid molecule of claim 55.
61. (New) The method of claim 6, wherein said contacting reduces the amount of the bcl-6 protein expressed by said bcl-6-expressing cell or of a ribonucleic acid (RNA) molecule encoding said bcl-6 protein.
62. (New) The method of claim 11, wherein said contacting reduces the amount of the bcl-6 protein expressed by said bcl-6-expressing cell or of a ribonucleic acid (RNA) molecule encoding said bcl-6 protein.
63. (New) The method of claim 15, wherein said contacting reduces the amount of the bcl-6 protein expressed by said bcl-6-expressing cell or of a ribonucleic acid (RNA) molecule encoding said bcl-6 protein.
64. (New) The method of claim 21, wherein said contacting reduces the amount of the bcl-6 protein expressed by said bcl-6-expressing cell or of a ribonucleic acid (RNA) molecule encoding said bcl-6 protein.
65. (New) The method of claim 26, wherein said contacting reduces the amount of the bcl-6 protein expressed by said bcl-6-expressing cell or of a ribonucleic acid (RNA) molecule encoding said bcl-6 protein.

APPLICANT(S): GEWIRTZ, Alan M.

SERIAL NO.: 10/593,578

FILED: June 4, 2007

Page 8

66. (New) The method of claim 32, wherein said contacting reduces the amount of the bcl-6 protein expressed by said bcl-6-expressing cell or of a ribonucleic acid (RNA) molecule encoding said bcl-6 protein.
67. (New) The method of claim 37, wherein said contacting reduces the amount of the bcl-6 protein expressed by said bcl-6-expressing cell or of a ribonucleic acid (RNA) molecule encoding said bcl-6 protein.
68. (New) The method of claim 44, wherein said contacting reduces the amount of the bcl-6 protein expressed by said bcl-6-expressing cell or of a ribonucleic acid (RNA) molecule encoding said bcl-6 protein.